OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goy on Bendamustine Plus Cytarabine as MCL Treatment

March 21st 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of bendamustine plus cytarabine as treatment for patients with mantle cell lymphoma.

Dr. Carey on Tailoring Treatment in Triple-Negative Breast Cancer

March 20th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Dr. Bauer on Evolution of Phase I Trials

March 20th 2017

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses how phase I clinical trial programs are evolving and becoming more beneficial for patients with cancer.

Dr. Luke on Adjuvant Therapies in Development for Melanoma

March 20th 2017

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

Dr. Kasper on Imatinib Versus Sorafenib in Sarcoma

March 18th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.

Dr. Hemphill on Molecular Profiling for Gastric Cancer Treatment

March 18th 2017

Brian Hemphill, MD, clinical oncologist, Tennessee Oncology, discusses molecular profiling for gastric cancer treatment.

Dr. Dadu on Treatment Options for Thyroid Cancer

March 18th 2017

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with anaplastic thyroid cancer.

Dr. Kennedy on Importance of SIRFLOX Study in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the importance of the SIRFLOX trial, which explored the efficacy of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres as treatment for patients with liver-metastatic colorectal cancer (CRC) versus standard frontline chemotherapy.

Dr. Albertsmeier on Radiotherapy Improving the Local Control of Sarcoma

March 17th 2017

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.

Dr. O'Neil on Stemness Inhibitors for CRC Treatment

March 17th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of Medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).

Dr. Bendell on Exciting Advancements in the Field of HCC

March 16th 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses exciting research and advancements in the field of hepatocellular carcinoma.

Dr. Koyfman on IMRT and SBRT Reirradiation for Head and Neck Cancer

March 16th 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.

Dr. Moore on the NOVA Trial for Ovarian Cancer

March 16th 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma

March 15th 2017

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

Dr. Goy on BR Plus Bortezomib for MCL Treatment

March 15th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of bendamustine and rituximab (Rituxan; BR) plus bortezomib (Velcade) as a potential treatment for patients with mantle cell lymphoma (MCL).

Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer

March 14th 2017

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the FDA approval of ribociclib (LEE011) for use in combination with letrozole as a frontline therapy for patients with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Dr. Ahn on Neoadjuvant Treatments for Patients With Gastric Cancer

March 13th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

March 13th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPC

March 13th 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.